Table 1. Summary of Pathway Analysis Results.
| Cancer | Number of Pathways Enriched in Males Only | Number of Pathways Enriched in Females Only | Number of Pathways Enriched in Both | Proportion of Significant Pathways Enriched in Only One Sex |
|---|---|---|---|---|
| LUAD | 115 | 36 | 28 | 0.84 |
| KICH | 96 | 27 | 37 | 0.77 |
| LIHC | 170 | 21 | 59 | 0.76 |
| HNSC | 97 | 57 | 101 | 0.6 |
| KIRC | 75 | 78 | 159 | 0.49 |
| Pan-Cancer | 69 | 22 | 123 | 0.43 |
| THCA | 45 | 51 | 148 | 0.39 |
| LUSC | 29 | 22 | 185 | 0.22 |
This table details the number of pathways found enriched (P < 0.05) in male, female, or both tumors in each of the 7 cancers considered. The proportion discordant measures the proportion of pathways enriched significantly in only one sex out of all pathways significantly enriched.